2025 United States Automation In Biopharmaceutical Market Revenue Opportunities Report
Description
The 2025 United States Automation In Biopharmaceutical Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Automation in Biopharmaceutical Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the automation segment of the biopharmaceutical market in the United States are Johnson & Johnson, Pfizer, McKesson Corporation, and Omnicell. Johnson & Johnson is investing $55 billion through 2029 to expand AI-backed biologics manufacturing, including four new U.S. plants, emphasizing scalable production and supply chain resilience. Pfizer aggressively integrates AI across clinical development and manufacturing, boosting throughput by 20% and reducing cycle time by 25% using generative AI platforms hosted on AWS. McKesson, headquartered in Texas, leads in pharmaceutical distribution and pharmacy automation, focusing on medication management and inventory optimization to streamline workflows and improve safety. Omnicell, based in California, excels in pharmacy automation with robotic dispensing and medication adherence systems, addressing labor shortages and clinical outcomes with adoption by major health systems.
These companies emphasize intelligent automation to enhance operational efficiency, compliance, and cost reduction in regulated biopharma environments. Pfizer and J&J focus heavily on AI in drug manufacturing and clinical workflows, while McKesson and Omnicell drive automation in pharmacy dispensing and medication management. Their technologies leverage AI, robotics, and data analytics to streamline complex pharmaceutical and biopharmaceutical processes, ensuring compliance with regulatory standards such as FDA requirements. This convergence of AI and automation significantly advances biopharmaceutical production, quality control, and supply chain robustness in the United States market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Automation in Biopharmaceutical Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the automation segment of the biopharmaceutical market in the United States are Johnson & Johnson, Pfizer, McKesson Corporation, and Omnicell. Johnson & Johnson is investing $55 billion through 2029 to expand AI-backed biologics manufacturing, including four new U.S. plants, emphasizing scalable production and supply chain resilience. Pfizer aggressively integrates AI across clinical development and manufacturing, boosting throughput by 20% and reducing cycle time by 25% using generative AI platforms hosted on AWS. McKesson, headquartered in Texas, leads in pharmaceutical distribution and pharmacy automation, focusing on medication management and inventory optimization to streamline workflows and improve safety. Omnicell, based in California, excels in pharmacy automation with robotic dispensing and medication adherence systems, addressing labor shortages and clinical outcomes with adoption by major health systems.
These companies emphasize intelligent automation to enhance operational efficiency, compliance, and cost reduction in regulated biopharma environments. Pfizer and J&J focus heavily on AI in drug manufacturing and clinical workflows, while McKesson and Omnicell drive automation in pharmacy dispensing and medication management. Their technologies leverage AI, robotics, and data analytics to streamline complex pharmaceutical and biopharmaceutical processes, ensuring compliance with regulatory standards such as FDA requirements. This convergence of AI and automation significantly advances biopharmaceutical production, quality control, and supply chain robustness in the United States market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
